Evidence map›Paper›PMID 26270298›Full record

ReviewAmerican journal of public health2015

How Stigma Surrounding the Use of HIV Preexposure Prophylaxis Undermines Prevention and Pleasure: A Call to Destigmatize "Truvada Whores".

Sarah K Calabrese, Kristen Underhill

Open access · greenAbstract readReview
In one paragraph

Review in American journal of public health, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 162 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
162citing papers in PubMed, 4 pooled it
12.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

162 citing papers in PubMed, 4 syntheses or guidelines pooled it, 299 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Perceptions of DoxyPEP use Among Racial & Ethnic Minority Patients.Journal of racial and ethnic health disparities · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Ultra-long-acting injectable, biodegradable, and removable in-situ forming implant with cabotegravir for HIV prevention.Journal of controlled release : official journal of the Controlled Release Society · 2025
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

102 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Sarah K CalabreseSarah K. Calabrese is with the Yale School of Public Health, New Haven, CT. Kristen Underhill is with Yale Law School, New Haven. Both are affiliates of the Center for Interdisciplinary Research on AIDS at Yale University, New Haven.
Kristen UnderhillSarah K. Calabrese is with the Yale School of Public Health, New Haven, CT. Kristen Underhill is with Yale Law School, New Haven. Both are affiliates of the Center for Interdisciplinary Research on AIDS at Yale University, New Haven.
Yale University · US

Funding

Using Coincidence Analysis to Investigate Factors Affecting PrEP Initiation and Continuation in Southern ending the Epidemic CountiesP30MH062294 · NIMH · YALE UNIVERSITY · PI Trace S Kershaw · 2001 to 2026
$48.5M
PrEP for HIV Prevention in MSM: Mixed-Methods Study of Behavior & Message FramingK01MH093273 · NIMH · YALE UNIVERSITY · PI UNDERHILL, KRISTEN · 2011 to 2015
$873k
Intervention to Promote PrEP Awareness and Equitable Prescription among ProvidersK01MH103080 · NIMH · YALE UNIVERSITY · PI CALABRESE, SARAH K. · 2014 to 2017
$634k
NIMHD NIH HHS L60 MD008519NIMH NIH HHS K01 MH093273NIMH NIH HHS K01MH093273NIMH NIH HHS K01 MH103080NIMH NIH HHS K01MH103080NIMH NIH HHS P30 MH062294NIMH NIH HHS P30MH062294
6 · The paper itself

Abstract

Antiretroviral preexposure prophylaxis (PrEP; emtricitabine and tenofovir disoproxil fumarate [Truvada]) prevents HIV without penalizing sexual pleasure, and may even enhance pleasure (e.g., by reducing HIV-related anxiety). However, concern about sexual risk behavior increasing with PrEP use (risk compensation) and corresponding stereotypes of promiscuity may undermine PrEP's preventive potential. In this commentary, we review literature on sexual behavior change accompanying PrEP use, discuss risk compensation concerns and the "Truvada whore" stereotype as PrEP barriers, question the appropriateness of restricting PrEP access because of risk compensation, and consider sexual pleasure as a benefit of PrEP, an acceptable motive for seeking PrEP, and a core element of health. It is essential for science to trump stereotypes and sex-negative messaging in guiding decision-making affecting PrEP access and uptake.

Indexed as

Emtricitabine, Tenofovir Disoproxil Fumarate Drug CombinationSexual BehaviorSocial StigmaAnti-HIV AgentsFemaleHIV InfectionsHumansMalePleasurePre-Exposure ProphylaxisStereotypingAnti-HIV AgentsEmtricitabine, Tenofovir Disoproxil Fumarate Drug Combination

Identifiers

PMID26270298
PMCPMC4566537
OpenAlexW2116518142

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.